Cigarette Smoking and Protection from Parkinson's Disease:False Association or Etiologic Clue?
Neurol 45:1041-1051, Morens,D.M.,et al, 1995
SGLT2 Inhibitor Use and Risk of Dementia and Parkinson Disease Among Patients With Type 2 Diabetes
Neurol 103:e209805, Kim,H.K.,et al, 2024
Complete Evaluation of Dementia: PET and MRI Correlation and Diagnosis for the Neuroradiologist
AJNR 42:998-1007, Oldan, J.D.,et al, 2021
Diagnosis and Management of Dementia
JAMA 322:1589-1599, Arvanitakis, Z.,et al, 2019
Visuoperception Test Predicts Pathologic Diagnosis of Alzheimer Disease in Corticobasal Syndrome
Neurol 83:510-519, Boyd, C.D.,et al, 2014
Deep-Brain Stimulation - Entering the Era of Human Neural-Network Modulation
NEJM 371:1369-1373, Okun, M.S., 2014
Degenerative Diseases of the Nervous System, Alzheimer Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1063, Ropper, A.H.,et al, 2014
TREM2 Variants in Alzheimers Disease
NEJM 368:117-127, Guerreiro, R.,et al, 2013
Variant of TREM2 Associated with the Risk of Alzheimers Disease
NEJM 368:107-116, Jonsson, T.,et al, 2013
Variant TREM2 as Risk Factor for Alzheimers Disease
NEJM 368:182-184, Neumann, H. & Daly, M., 2013
Memory Enhancement and Deep-Brain Stimulation of the Entorhinal Area
NEJM 366:502-510, Suthana,N.,et al, 2012
Lifelong Management of Amyloid-Beta Metabolism to Prevent Alzheimers Disease
NEJM 367:864-866, Gandy, S., 2012
Clinical and Biomarker Changes in Dominantly Inherited Alzheimers Disease
NEJM 367:795-804,864, Bateman, R.J.,et al, 2012
Alzheimers Disease
NEJM 362:329-344, Querfurth,H.W. &LaFerla,F.M., 2010
Dysexecutive Syndrome: Diagnostic Criteria and Validation Study
Ann Neurol 68:855-864, Godefroy,O.,et al, 2010
Disease-Modifying Therapies for Alzheimers: New Drugs on the Horizon
Practical Neurology 7:16-23, Christensen,D.B., 2008
Genetic Factors in Alzheimer's Disease
NEJM 352: 862-863, 884, Bird, T., 2005
Neuronal Loss Is Greater in the Locus Coeruleus Than Nucleus Basalis and Substantia Nigra in Alzheimer and Parkinson Diseases
Arch Neurol 60:337-341, 320, Zarow,C.,et al, 2003
Alzheimer's Disease and Parkinson's Disease
NEJM 348:1356-1364, Nussbaum,R.L. &Ellis,C.E., 2003
Epilepsy Presenting as AD: Neuroimaging, Electroclinical Features, and Response to Treatment
Neurol 58:298-301, Hogh,P.,et al, 2002
Alzheimer Disease
JAMA 287:2335-2338, Cummings,J.L. &Cole,G., 2002
Potentially Reversible Conditions in 1000 Consecutive Memory Clinic Patients
JNNP 73:390-394, Hejl,A.,et al, 2002
Stem-Cell Research: Drawing the Line
Lancet 358:163,217, Greenberg,D.S., 2001
Progression of Parkinsonian Signs in Alzheimer's Disease
Neurol 54:1284-1289, Wilson,R.S.,et al, 2000
Screening for Dementia with the Memory Impairment Screen
Neurol 52:231-238,224, Buschke,H.,et al, 1999
Progressive Aphasia with Rapidly Progressive Dementia in a 49 Year Old Woman
JNNP 66:238-243, Greene,J.D.W.,et al,, 1999
Medial Temporal Lobe Atrophy on MRI in Dementia with Lewy Bodies
Neurol 52:1153-1158, Barber,R.,et al, 1999
Molecular Basis of the Neurodegenerative Disorders
NEJM 340:1970-1980, Martin,J.B., 1999
Nuclear Medicine in Neurology and Psychiatry
Lancet 354:1107-1111, Costa,D.C.,et al, 1999
A Clinical Role for 99mTC-HMPAO SPECT in the Investigation of Dementia
JNNP 64:306-313, Talbot,P.R.,et al, 1998
Is Exposure to Aluminum a Risk Factor for the Development of Alzheimer Disease? -Yes
Neurol 55:740-742, Forbes,W.F.&Hill,G.B., 1998
Is Exposure to Aluminum a Risk Factor for the Development of Alzheimer Disease? -No
Arch Neurol 55:737-739, 7421998., Munoz,D.G., 1998
Smoking and Risk of Dementia and Alzheimer's Disease in a Population-Based Cohort Study:The Rotterdam Study
lancet 351:1840-1843, Ott,A.,et al, 1998
Early Dopaminergic Drug-Induced Hallucinations in Parkinsonian Patients
Neurol 51:811-814, Goetz,C.G.,et al, 1998
Exploring the Etiology of Alzheimer Disease Using Molecular Genetics
JAMA 277:825-831, Lendon,C.L.,et al, 1997
Assessment of CSF Levels of Tau Protein in Mildly Demented Patients with Alzheimer's Disese
Neurol 48:632-635, Galasko,D.,et al, 1997
A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
NEJM 336:1216-1222, 12451997., Sano,M.,et al, 1997
Midline Cerebral Morphometry Distinguishes Frontotemporal Dementia and Alzheimer's Disease
Neurol 48:978-985, Kaufer,D.I.,et al, 1997
Frontotemporal Dementia and Early Alzheimer Disease:Differentiation with Frontal Lobe H-1 MR Spectroscopy
Radiology 203:829-836, Ernst,T.,et al, 1997
Incorrect Diagnosis of Alzheimer's Disease:A Clinicopathologic Study
Arch Neurol 53:35-42, Klatka,L.A.,et al, 1996
Dementia in a 58-year-old Woman
Lancet 347:236, Sellal,F.,et al, 1996
Lewy Body Disease and Dementia
Arch Int Med 156:487-493, Kalra,S.,et al, 1996
Dementia and Adult-Onset Unprovoked Seizures
Neurol 46:727-730, Hesdorffer,D.C.,et al, 1996
Elevated Risk of Alzheimer's Disease Among Workers with Likely Electromagnetic Field Exposure
Neurol 47:1477-1481, Sobel,E.,et al, 1996
Electromagnetic Field Exposure May Cause Increased Production of Amyloid Beta & Eventually lead to Alzheimer's Disease
Neurol 47:1594-1600, Sobel,E.&Davanipour,Z., 1996
Diagnosis and Evaluation of Dementia
Neurol 45:211-218, Corey-Bloom,J.,et al, 1995
Dementia:The Failing Brain
Lancet 345:1481-1484, Cummings,J.L., 1995
Image Analysis of B-Amyloid Load in Alzheimer's Disease and Relation to Dementia Severity
Lancet 346:1524-1528, Cummings,B.J.&Cotman,C.W., 1995
Electroencephalography as an Aid in the Exclusion of Alzheimer's Disease
Arch Neurol 51:280-284, Robinson,D.J.,et al, 1994